

Partial primary structure of human pregnancy zone protein: Extensive sequence homology with human α_2 -macroglobulin

(plasma proteins/evolution/acute-phase proteins)

LARS SOTTRUP-JENSEN*, JØRGEN FOLKERSEN†, TORSTEN KRISTENSEN‡, AND BRIAN F. TACK‡

*Department of Molecular Biology, University of Aarhus, 8000, Aarhus C, Denmark; †Institute of Medical Microbiology, University of Odense, 5000, Odense, Denmark; and ‡Department of Immunology, Scripps Clinic and Research Foundation, La Jolla, CA 92037

Communicated by Frank W. Putnam, August 9, 1984

ABSTRACT Human pregnancy zone protein (PZP) is a major pregnancy-associated protein. Its quaternary structure (two covalently bound 180-kDa subunits, which are further non-covalently assembled into a tetramer of 720 kDa) is similar to that of human α_2 -macroglobulin (α_2 M). Here we show, from the results of complete or partial sequence determination of a random selection of 38 tryptic peptides covering 685 residues of the subunit of PZP, that PZP and α_2 M indeed are extensively homologous. In the stretches of PZP sequenced so far, the degree of identically placed residues in the two proteins is 68%, indicating a close evolutionary relationship between PZP and α_2 M. Although the function of PZP in pregnancy is largely unknown, its close structural relationship to α_2 M suggests analogous proteinase binding properties and a potential for being taken up in cells by receptor-mediated endocytosis. In this regard our studies indicate a bait region in PZP significantly different from that present in α_2 M. PZP could be the human equivalent of the acute-phase α -macroglobulins (e.g., rat α_2 M and rabbit α_1 M) described earlier.

Human "pregnancy zone protein" (PZP)[§] is one of the major pregnancy-associated plasma proteins. PZP was first described in 1959 by Smithies (2) who, upon zone-electrophoresis in starch gels, detected a characteristic band from the sera of some pregnant women. Subsequent work showed that PZP was a prominent constituent of late-pregnancy sera (3, 4). In healthy non-pregnant females and in males, PZP is present in trace amounts only (females: 10–30 mg/liter of plasma; males: <10 mg/liter of plasma) (5). During pregnancy, the plasma concentration of PZP increases and may reach levels of 1000–1400 mg/liter just before term (5–7). Small amounts of PZP have been prepared from pregnancy serum and plasma or from placental extracts by elaborate conventional procedures or more recently by immunoabsorbent techniques (8–16). PZP is a glycoprotein of α_2 -mobility (2–4, 8, 9) containing 10–12% carbohydrate (11–13). Preparations of PZP when subjected to denaturation under non-reducing conditions display a 360-kDa molecular species (12, 13, 16) along with high molecular mass aggregates (13). Upon reduction, 180-kDa subunits are observed (12, 13, 16), which occasionally are partially cleaved to 90-kDa fragments, as reported by Bohn and Winckler (ref. 13; also unpublished data). From gel chromatography and gradient-pore PAGE studies under non-denaturing conditions, Stimson and Farquharson (16) suggested that PZP was a tetrameric protein containing 180-kDa subunits. These features of PZP are strikingly similar to those of human α_2 -macroglobulin (α_2 M), a major proteinase binding protein containing four identical 180-kDa subunits of known primary structure (17), and indicate that PZP and α_2 M might be related proteins. This is further suggested by the apparent existence of common anti-

genic determinants in PZP and α_2 M (ref. 18; unpublished data).

Proteins structurally and functionally related to human α_2 M have been found in the plasma of members of all major vertebrate taxa (19). Two distinct α -macroglobulins (α Ms) having slightly different electrophoretic mobility have been described in the rat (α_1 M and α_2 M) (20–22), the rabbit (α_1 M and α_2 M) (23, 24), the dog (α_1 M and α_2 M) (25), and the pig ("slow" α M and "fast" α M) (26). Of the two α Ms found in the rat and the rabbit, rat α_2 M and rabbit α_1 M are acute-phase reactants, since their plasma levels are greatly increased during experimental inflammation and under a variety of stress conditions. In contrast, the plasma levels of rat α_1 M and rabbit α_2 M, like human α_2 M, are only slightly affected under these conditions (20–23, 27–32). The observation that the plasma concentration of rat α_2 M is increased during pregnancy (28–30) indicates that PZP and rat α_2 M could be functionally equivalent.

Here we demonstrate, from the results of sequence determination of an essentially random selection of tryptic peptides representing $\approx 47\%$ of the sequence of the subunit of PZP, that PZP and α_2 M indeed share many stretches of extremely similar sequence. This strongly suggests a close evolutionary relationship for PZP and α_2 M, even closer than that already recognized for α_2 M and the complement components C3 and C4 (17, 33).

MATERIALS AND METHODS

Human PZP was isolated by immunoabsorbent techniques as described earlier (15) from pooled late-pregnancy serum. Following extensive washing with 0.1 M barbital acetate, pH 8.5/1 M NaCl, PZP was eluted from the column of Sepharose-bound anti-PZP with 3 M MgCl₂/0.6 M NaCl, pH 4.8 (15). Contaminating α_2 M (<5%) was removed by passing the dialyzed eluate through a column of Sepharose-bound anti- α_2 M. Reducing NaDodSO₄/PAGE showed that this preparation, which was used for the tryptic digest described below, contained about 30% 90-kDa cleavage products.

Hydrolysates of proteins and peptides were analyzed on a Beckman 6300 instrument. Automated sequenced analyses on 1- to 5-nmol samples of proteins and peptides were performed on a Beckman 890D Sequencer in the presence of pretreated Polybrene (34) using the 0.1 M Quadrol program supplied by the manufacturer. Phenylthiohydantoin derivatives of amino acids were analyzed by HPLC on a 4 × 250 mm column packed with DuPont Zorbax C₁₈ material in a Hewlett-Packard 1084B instrument equipped with a fixed

Abbreviations: PZP, pregnancy zone protein (human); α M, α -macroglobulin; C, complement.

[§]The pregnancy zone protein (PZP) is also known as pregnancy-associated α_2 -glycoprotein, pregnancy-associated globulin, α_2 -acute-phase glycoprotein, α_2 -pregnoglobulin, pregnancy-associated α -macroglobulin, schwangerschafts protein-3, Xh antigen, and Pa-1 (1).

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

wavelength detector (254 nm) essentially as described (35). Reagents and solvents for sequence analysis were purchased from Beckman and from Burdick and Jackson (Muskegon, MI).

EXPERIMENTAL

PZP (50 nmol of 180-kDa subunit) containing no detectable impurities was reduced with dithiothreitol and alkylated with [^3H]ICH₂COOH essentially as described for the sequence analysis of $\alpha_2\text{M}$ (34). After gel chromatography on a 2.5 \times 100 cm column of Sephadex G-25 F (Pharmacia), the void volume fraction (50 ml) was digested with 0.2 mg of *N*-tosylphenylalanyl chloromethyl ketone-treated bovine trypsin (Worthington) for 2 hr at 22°C. The digestion was stopped by the addition of 0.2 mg of soybean trypsin inhibitor (Worthington) and the solution was freeze dried. The tryptic peptides were resolved into 29 pools by DEAE-Sephacel chromatography in NH₄HCO₃-containing buffers (34) (Fig. 1). Following freeze drying, the peptides in selected pools were redissolved in 0.5 ml of a 1% aqueous trifluoroacetic acid solution (Pierce) and further separated by HPLC on a 8 \times 250 mm column of Vydac C₄ material (300-nm pore size). The peptides were eluted at 43°C with a linear gradient of




FIG. 1. Separation of tryptic peptides from 50 nmol of dithiothreitol-reduced and [^3H]carboxymethylated PZP on a 0.75 \times 22 cm column of DEAE-Sephacel. The column was equilibrated with 10 mM NH₄HCO₃ and eluted with gradients of NH₄HCO₃: from 10 mM to 250 mM (100 ml + 100 ml) and from 250 mM to 500 mM (50 ml + 50 ml). The column was finally eluted with 0.25 M NH₄HCO₃/3 M guanidine-HCl (\uparrow). The flow rate was 6 ml/hr and 1.5-ml fractions were collected. The separation was monitored by measuring the absorbance at 230 nm and by determining the amount of radioactivity in 10- μ l aliquots from each fraction. Except for pool 29, which was first resalted into 0.1 M NH₄HCO₃ by Sephadex G-25 gel chromatography, all pools were directly freeze dried. Selected pools were further separated by reverse-phase HPLC (results not shown). Pools 1-3, 6, 21, 25, 27, and 28 were not investigated. No pure peptides were recovered from pools 14, 15, 19, 20, and 29. The stretches of sequence from PZP shown in Fig. 2 were obtained from the following pools: pool 4: 71-85, 86-92, 129-136, 137-149, 285-296, 317-326, and 338-352; pool 5: 782-788, 1125-1129, and 1298-1306; pools 7 and 8: 23-45, 160-181, 485-498, 499-516, 665-687, 892-917, and 1168-1187; pools 9 and 10: 192-203, 215-235, 242-251, 1142-1156, 1307-1321, and 1322-1333; pools 11 and 12: 428-461, 997-1008, and 1100-1113; pool 13: 49-70, 303-316, and 744-764; pools 16 and 17: 395-427, 807-818, and 879-891; pool 18: 518-553; pool 22: 252-274 and 710-743; pool 23: 819-830; pool 24: 603-647; pool 26: 1426-1451. The numbering of stretches in PZP is that of $\alpha_2\text{M}$.

CH₃CN [from 10% CH₃CN/90% 0.1% trifluoroacetic acid to 70% CH₃CN/30% 0.1% trifluoroacetic acid (36)] at a flow rate of 2 ml/min. All separations were performed with a Waters instrument equipped with a 214-nm fixed wavelength detector.

RESULTS

The amino acid composition of PZP, prepared as in ref. 15, is given in Table 1 and is in fair agreement with that determined earlier by Von Schoultz and Stigbrand (12). The composition of PZP is remarkably similar to that of human $\alpha_2\text{M}$ (17). Although the preparation of PZP contained \approx 30% cleaved subunits, the sequence of the first 19 residues could be confidently identified by using "background" subtraction as in ref. 37 (Fig. 2). The NH₂-terminal sequences of PZP and human $\alpha_2\text{M}$ are strongly homologous (the sequence of PZP starts at position 4 in human $\alpha_2\text{M}$). The extent of homology in this region between human $\alpha_2\text{M}$ and PZP is about the same as for human $\alpha_2\text{M}$ and rat $\alpha_2\text{M}$ (17).

To investigate if PZP and $\alpha_2\text{M}$ would share extended stretches of homologous sequence, a tryptic digest of reduced and [^3H]carboxymethylated PZP was investigated. Although such a digest would be exceedingly complex and a number of larger hydrophobic peptides were likely to be recovered in a low yield (34), an essentially random selection of relatively small peptides would be obtained. The tryptic peptides from PZP were initially fractionated by DEAE-Sephacel ion-exchange chromatography (Fig. 1) followed by final purification by reverse-phase HPLC (data now shown).

The results of complete or partial sequence determination of 38 pure tryptic peptides, accounting for 685 residues, are given in Fig. 2. In almost every case, even for the short peptides, the sequences obtained from PZP could be readily aligned with corresponding regions in the human $\alpha_2\text{M}$ sequence shown in Fig. 2 (data from ref. 17). In a few instances small deletions had to be introduced in either sequence to obtain maximal alignment of the sequences. These areas (residues 256-260, 401-407, and 618-630) probably constitute parts of the surface regions in the two proteins. One major 28-residue tryptic peptide did not contain arginyl or lysyl residues and probably represents the COOH-terminal tryptic peptide of PZP. This peptide matches well with $\alpha_2\text{M}$

Table 1. Amino acid composition of PZP and $\alpha_2\text{M}$

Amino acid	PZP*	$\alpha_2\text{M}^\dagger$
Asx	131	115
Thr	96	100
Ser	129	122
Glx	189	188
Pro	78	76
Gly	87	90
Ala	99	92
Cys	20	24
Val	118	137
Met	25	25
Ile	61	57
Leu	141	134
Tyr	55	56
Phe	65	62
Lys	76	87
His	31	39
Trp	ND	11
Arg	54	46

ND, not determined.

*The result of duplicate analyses of the material used for the tryptic digest of PZP (6 M HCl/0.1% phenol; 110°C, 20 hr). No correction has been made for hydrolytic loss or incomplete hydrolysis. The composition is calculated on the basis of 54 residues of arginine.

† Calculated from the complete sequence of $\alpha_2\text{M}$ (17).



FIG. 2. Alignment of completely or partially sequenced tryptic peptides from PZP with corresponding stretches from α_2 M. The complete sequence of human α_2 M is from ref. 17. The amino acid sequences are given in the single-letter code (38). X denotes an unidentified amino acid residue. Identically placed residues in the two proteins are underlined. The first 19 residues of PZP were determined by sequenator analysis of the intact preparation. In addition to a major threonine residue, minor amounts of asparagine, serine, and glycine were also observed in step 1.

and suggests a 2-residue deletion at position 1448–1449 in the α_2 M sequence. In some regions the sequences of longer stretches of PZP and α_2 M are nearly identical (e.g., the stretches corresponding to residues 5–41 and 710–764 of α_2 M). On the average the stretches determined contain 68% identically placed residues. About one-half of the dissimilar residues involve chemically similar residues or exchanges that retain a charged or hydrophilic residue at a given position. Of the expected 20–24 half-cystine residues in the PZP monomer, 18 have been determined, including the half-cystine residue that by analogy with α_2 M (17), presumably bridges two-subunits to form a 360-kDa half molecule. As seen from Fig. 3, the disulfide bridge pattern of PZP is likely to be very similar to that of α_2 M. The half-cystine residue at position 540 has no counterpart in α_2 M. Since no peptides have been recovered from the region 923–996, which in α_2 M is largely constituted by a 56-residue tryptic peptide containing the β -cysteinyl- γ -glutamyl thiol ester structure (17, 39), it is not yet apparent from the sequence data if PZP also contains such a structure. When the PZP preparation used in these studies was examined for its ability to incorporate [3 H]CH₃NH₂ covalently, <0.02 mol of CH₃NH₂ per mol of PZP subunit was bound. Of course, the method of purification of PZP might be expected to inactivate its putative proteinase-inhibiting activity and cleave any internal thiol ester bonds.

The partial sequence of a major half-cystine-containing peptide showed only a modest degree of homology with α_2 M and was tentatively located at position 665–687. The region 681–686 in α_2 M contains the primary sites of proteolytic cleavage and has been referred to as the bait region (17). The results of NH₂-terminal sequence determination of the present PZP preparation, which contained 30% 90-kDa cleavage products, did not allow the identification of the sequences at

the cleavage sites. Further evidence in favor of a bait region in PZP was obtained from an experiment in which PZP was treated with a 2-fold molar excess of trypsin for 2 min. Upon reducing NaDodSO₄/PAGE, the complete disappearance of the 180-kDa subunit was accompanied by a corresponding increase in the amount of 90-kDa fragments (results not shown).

No tryptic peptides were recovered from the long stretches 1168–1297 and 1334–1425. During the sequence determination of α_2 M the recovery of tryptic peptides from these regions was low due to their large size and their tendency to form aggregates (34). As seen in Fig. 1, a set of strongly retained peptides could be eluted from the DEAE-Sephacel column by 3 M guanidine·HCl/0.25 M NH₄HCO₃. However, none of these peptides could be recovered in appreciable yield after an attempt of purification by reverse-phase HPLC.

DISCUSSION

The results of NH₂-terminal sequence determination and partial or complete sequence determination of tryptic peptides from highly purified PZP show that this human plasma protein is a close homolog of human α_2 M. The 38 peptides presented in Fig. 2 account for 685 residues of the \approx 1450 residues of the subunit of PZP. Sixty-eight percent of the residues in these peptides are identical to those of α_2 M. Although no peptides were recovered from certain areas of PZP, notably the COOH-terminal half, it is likely that the overall degree of sequence homology between PZP and α_2 M will turn out to be very high. Including chemically similar residues (D = E, T = S, V = M = I = L, F = Y = H = W, and K = R), the extent of homology increases to about 76%, indicating that the subunits of PZP and α_2 M have essentially the same tertiary structure. Both proteins appear to have the




FIG. 3. Schematic representation of the 180-kDa subunit of α_2M , emphasizing the disulfide bridge pattern (data from ref. 17). Half-cystine residues found in PZP are labeled by an asterisk (*). The activation cleavage area (▼) and the β -cysteinyl- γ -glutamyl thiol ester site (▽) of α_2M are indicated.

same quaternary structure (identical 180-kDa units pair-wise disulfide bridged and further assembled to form tetramers of 720 kDa) (16, 17).

It has been pointed out recently that the proteins human α_2M , murine C3, and human or murine C4, which all contain an internal reactive β -cysteinyl- γ -glutamyl thiol ester (40–43), display large segments of homologous sequence, indicating a common evolutionary origin (33). However, the homologous regions of α_2M and C3, which account for 75% and 67% of their sequence, respectively, only contain 19–31% identically placed residues (33). The mutual sequence identity between C3 (44, 45), C4 (46), and an \approx 491-residue segment of C5, spanning the β -chain- α -chain junction (47) is 35–40%, indicating that these proteins, which all circulate as multiple-chain 190- to 200-kDa plasma proteins, could constitute one subset of a group of proteins related to α_2M , whereas α_2M , PZP, α M from different animal species, and perhaps the proteinase binding protein from chicken egg white, ovostatin (48), could constitute another subset. This subset is characterized as tetrameric proteins containing subunits of \approx 180 kDa, which may or may not be proteolytically processed. Interestingly, both ovostatin (48) and C5 (49) apparently do not contain an internal thiol ester.

Preparations of PZP have immunosuppressive properties under certain experimental conditions (e.g., by inhibiting the phytohemagglutinin and concanavalin A stimulation of T lymphocytes) (50, 51). These properties are thought to be of importance in the maintenance of the immunologically privileged status of the fetus (50–52). Similar phenomena have been reported for α_2M (53), and it has been suggested that these properties might reside in peptide(s) associated with or liberated from α_2M during α_2M -proteinase complex formation (54). It is not yet clear whether the effects observed with α_2M preparations are due to α_2M or are due to a slight contamination with PZP. Most likely, PZP, by virtue of its close similarity with α_2M , has been present as a contaminant in most α_2M preparations utilized so far.

In contrast to α_2M (31, 32, 55), highly elevated plasma levels of PZP are found during pregnancy. A less-pronounced increase in the plasma level of PZP is found in females using oral contraceptives, in males who receive estrogens during treatment for prostatic cancer, and in a variety of surgical and malignant conditions (56–59). These features indicate that PZP could be the human equivalent of the acute-phase protein rat α_2M that is also elevated in pregnancy (28–30). Like human α_2M , the plasma concentration of rat α_1M is relatively stable during the acute-phase response (20–22). For both rat α M, the liver is probably the major site of synthesis (60–62) as it is for α_2M (unpublished data). Although PZP has been localized in the villous parenchymal tissue of the placenta and in trophoblasts (63), this organ is probably not the site of its synthesis (64). Though *in vitro* estrogen-dependent synthesis of PZP has been demonstrated in cultures of human leukocytes (65–67), synthesis of PZP by the liver hepatocytes is probably quantitatively most important (68, 69).

The demonstration here that human plasma contains a tetrameric protein, PZP, which is strongly related to α_2M in terms of primary structure, subunit organization (12, 13, 16), and potential to become specifically cleaved near the middle of its subunits, as also recognized earlier (13), suggests that

the function of PZP, although still largely obscure, might be analogous to that of α_2M . In particular, investigations on the ability of PZP to form complexes with proteinases and the possible specific clearance of these complexes by receptor-mediated endocytosis will be important for defining the role of PZP in pregnancy. Furthermore, the study of the gene structures of PZP and α_2M may contribute to a deeper understanding of the structural elements that control the expression of these two proteins.

Part of this work was carried out while L.S.-J. was a Visiting Investigator at the Department of Immunology, Scripps Clinic and Research Foundation. This work was supported by the Danish Science Research Council, by the NATO Science foundation, by the Danish Medical Science Research Council, and by U.S. Public Health Service Grant AI 19222 from the National Institutes of Health. This is publication no. 3521 IMM from the Research Institute of Scripps Clinic.

- Berne, B. H., Bohn, H., Hofmann, R., Klausch, B., Straube, W., Horne, C. H. W., Kasukawa, R., Rittner, C., Stimson, W. H. & Than, G. N. (1975) *Lancet* **i**, 367–368.
- Smithies, O. (1959) *Adv. Protein. Chem.* **14**, 65–133.
- Cooper, D. W. (1963) *Nature (London)* **200**, 892.
- DeAlvarez, R. R. & Thompson, I. E. (1964) *Obstet. Gynecol.* **23**, 640–645.
- Folkersen, J., Teisner, B., Grunnet, N., Grudzinskas, J. G., Westergaard, J. G. & Hindersson, P. (1981) *Clin. Chim. Acta* **110**, 139–145.
- Von Schoultz, B. (1974) *Am. J. Obstet. Gynecol.* **119**, 792–797.
- Than, G. N., Csaba, I. F., Szabo, D. G., Karg, N. J. & Novak, P. F. (1976) *Vox Sang.* **30**, 134–138.
- Kueppers, F. (1969) *Humangenetik* **7**, 98–103.
- Bohn, H. (1971) *Arch. Gynäk.* **210**, 440–457.
- Straube, W., Klausch, B., Hofmann, R. & Brock, J. (1972) *Arch. Gynäk.* **212**, 230–245.
- Stimson, W. H. & Eubank-Scott, L. (1972) *FEBS Lett.* **23**, 298–302.
- Von Schoultz, B. & Stigbrand, T. (1974) *Biochim. Biophys. Acta* **359**, 303–310.
- Bohn, H. & Winckler, W. (1976) *Blut* **33**, 377–388.
- Stigbrand, T., Damber, M.-G. & Von Schoultz, B. (1978) *Acta Chem. Scand.* **B32**, 717–719.
- Folkersen, J., Teisner, B., Ahrons, S. & Svehag, S.-E. (1978) *J. Immunol. Methods* **23**, 117–125.
- Stimson, W. H. & Farquharson, D. M. (1978) *Int. J. Biochem.* **9**, 839–843.
- Sottrup-Jensen, L., Stepanik, T. M., Kristensen, T., Wierzbicki, D. M., Jones, C. M., Lönblad, P. B., Magnusson, S. & Petersen, T. E. (1984) *J. Biol. Chem.* **259**, 8318–8327.
- Weström, B. R., Karlsson, B. W. & Ohlsson, K. (1982) *Hoppe-Seyler's Z. Physiol. Chem.* **364**, 375–381.
- Starkey, P. M. & Barrett, A. J. (1982) *Biochem. J.* **205**, 91–95.
- Ganrot, K. (1973) *Biochim. Biophys. Acta* **295**, 245–251.
- Gordon, A. H. (1976) *Biochem. J.* **159**, 643–650.
- Nelles, L. P. & Schnebli, H. P. (1982) *Hoppe-Seyler's Z. Physiol. Chem.* **363**, 677–682.
- Lebreton de Vonne, T. & Mouray, M. H. (1968) *C.R. Acad. Sci. (Paris) Ser. D.* **266**, 1076–1079.
- Bloth, B., Chesebro, B. & Svehag, S.-E. (1968) *J. Exp. Med.* **127**, 749–756.
- Ohlsson, K. (1971) *Biochim. Biophys. Acta* **236**, 84–91.
- Weström, B. (1979) *Hoppe-Seyler's Z. Physiol. Chem.* **360**, 1869–1878.
- Morelis, P., Ambrosioni, J.-C., Got, R. & Fontanges (1969) *C.R. Acad. Sci. (Paris) Ser. D.* **269**, 1453–1454.

28. Beaton, G. H., Selby, A. E., Veen, M. J. & Wright, A. M. (1961) *J. Biol. Chem.* **236**, 2005–2008.
29. Heim, W. G. (1962) *Nature (London)* **193**, 491.
30. Weimer, H. E. & Benjamin, D. C. (1965) *Am. J. Physiol.* **209**, 736–744.
31. Wilding, P., Adham, N. F., Mehl, J. W. & Haverback, B. J. (1967) *Nature (London)* **214**, 1226–1227.
32. Ganrot, P. O. & Bjerre, B. (1967) *Acta Obstet. Gynecol. Scand.* **46**, 126–137.
33. Sottrup-Jensen, L., Stepanik, T. M., Kristensen, T., Lønblad, P. B., Jones, C. M., Wierzbicki, D. M., Magnusson, S., Domdey, H., Wetsel, R. A., Lundwall, Å., Tack, B. F. & Fey, G. H. (1985) *Proc. Natl. Acad. Sci. USA* **82**, in press.
34. Sottrup-Jensen, L., Stepanik, T. M., Jones, C. M., Lønblad, P. B., Kristensen, T. & Wierzbicki, D. M. (1984) *J. Biol. Chem.* **259**, 8293–8303.
35. Zimmerman, C. L. & Pisano, J. J. (1977) *Methods Enzymol.* **47**, 45–51.
36. Mahoney, W. C. & Hermodson, M. A. (1980) *J. Biol. Chem.* **255**, 11199–11203.
37. Mortensen, S. B., Sottrup-Jensen, L., Hansen, H. F., Petersen, T. E. & Magnusson, S. (1981) *FEBS Lett.* **135**, 295–300.
38. IUPAC-IUB Commission on Biochemical Nomenclature (1968) *J. Biol. Chem.* **243**, 3557–3559.
39. Swenson, R. P. & Howard, J. B. (1980) *J. Biol. Chem.* **255**, 8087–8091.
40. Tack, B. F., Harrison, R. A., Janatova, J., Thomas, M. L. & Pahl, J. W. (1980) *Proc. Natl. Acad. Sci. USA* **77**, 5764–5768.
41. Sottrup-Jensen, L., Petersen, T. E. & Magnusson, S. (1980) *FEBS Lett.* **121**, 275–279.
42. Janatova, J. & Tack, B. F. (1981) *Biochemistry* **20**, 2394–2404.
43. Campbell, R. D., Gagnon, J. & Porter, R. R. (1981) *Biochem. J.* **199**, 359–370.
44. Lundwall, Å., Wetsel, R. A., Domdey, H., Tack, B. F. & Fey, G. H. (1984) *J. Biol. Chem.*, in press.
45. Wetsel, R. A., Lundwall, Å., Davidson, F. F., Tack, B. F., Gibson, T. & Fey, G. H. (1984) *J. Biol. Chem.*, in press.
46. Belt, K. T., Carroll, M. C. & Porter, R. R. (1984) *Cell* **36**, 907–914.
47. Lundwall, Å., Wetsel, R. A., Kristensen, T., Whitehead, A. S., Woods, D., Ogden, R. C., Colten, H. R. & Tack, B. F. (1985) *J. Biol. Chem.*, in press.
48. Nagase, H., Harris, E. D., Woessner, F. J. & Brew, K. (1983) *J. Biol. Chem.* **258**, 7481–7489.
49. DiScipio, R. G., Smith, C. A., Müller-Eberhard, H. J. & Hugli, T. E. (1983) *J. Biol. Chem.* **258**, 10629–10636.
50. Von Schoutz, B., Stigbrand, T. & Tärnvik, A. (1973) *FEBS Lett.* **38**, 23–26.
51. Stimson, W. H. (1976) *Clin. Exp. Immunol.* **25**, 199–206.
52. Stimson, W. H. (1972) *Lancet* **i**, 684.
53. Hubbard, W. H., Hess, A. D., Hsia, S. & Amos, D. B. (1981) *J. Immunol.* **126**, 292–299.
54. Hubbard, W. H., Anderson, B. D., Balber, A. E., Proud, G. M., Alomran, A. J. & Shenton, B. K. (1983) *Ann. N.Y. Acad. Sci.* **421**, 332–339.
55. Horne, C. H. W., Howie, P. W., Weir, P. J. & Goudie, R. B. (1970) *Lancet* **i**, 49–50.
56. Bohn, H. (1973) *Blut* **26**, 205–209.
57. Horne, C. H. W., McLay, A. L. C., Tavadia, H. B., Carmichael, I., Mallingson, A. C., Yeung Laiwah, A. A. C., Thomas, M. A. & McSween, R. N. M. (1973) *Clin. Exp. Immunol.* **13**, 603–611.
58. Berne, B. H. (1974) *Fed. Proc. Fed. Am. Soc. Exp. Biol.* **33**, 290.
59. Horne, C. H. W., Bohn, H., McLay, A. L. C., Wood, E. H. & Thomson, W. D. (1975) *Behring Inst. Mitt.* **58**, 50–53.
60. Weimer, H. E. & Benjamin, D. C. (1965) *Nature (London)* **206**, 1221–1222.
61. Benjamin, D. C. & Weimer, H. E. (1966) *Nature (London)* **209**, 1032–1033.
62. Andus, T., Gross, V., Tran-Thi, T.-A. & Heinrich, P. C. (1983) *FEBS Lett.* **151**, 10–14.
63. Lin, T.-M. & Halbert, S. P. (1976) *Science* **193**, 1249–1253.
64. Lin, T.-M., Halbert, S. P. & Kiefer, D. (1976) *J. Clin. Invest.* **57**, 466–472.
65. Stimson, W. H. & Blackstock, T. L. (1975) *Experientia* **31**, 371–373.
66. Horne, C. H. W., Thomson, A. W., Towles, C. H., MacMillan, F. K. & Gibb, L. M. (1978) *Scand. J. Immunol.* **8**, 75–80.
67. Lundgren, E., Damber, M.-G., Roos, G., Von Schoutz, B., Stigbrand, T., Nilsson, K. & Alexander, T. T. (1979) *Int. J. Cancer* **24**, 45–48.
68. Stimson, W. H., Farquharson, D. M., Shepherd, A. & Anderson, J. M. (1979) *J. Clin. Lab. Immunol.* **2**, 235–238.
69. Von Schoutz, B. & Stigbrand, T. (1982) in *Pregnancy Proteins*, eds. Grudzinskas, J. G., Teisner, B. & Seppälä, M. (Academic, Sydney), pp. 167–175.